OncologyTube Professional - Patients Click Here
353,968 video views
VJHemOnc: Videos
Allogeneic stem cell transplantation (allo-SCT) is the only curative option for many patients with hematological malignancies. It is therefore crucial that allo-SCT is utilized appropriately to optimize efficacy and limit toxicity. Here, Thomas Luft, MD, PhD, from Heidelberg University, Heidelberg, Germany, identifies the key contributor in graft-v...
by:VJHemOnc | 0 views
A picture can say a thousand words and, in this case, it is all too true; understanding tumour metabolism, bone marrow involvement and disease progression can all be captured through imaging techniques. At the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Elena Zamagni, MD, PhD, ...
by:VJHemOnc | 9 views
Although the rates of progression-fre​e survival are steadily increasing, the majority of multiple myeloma (MM) patients still face relapse. Here, Neil van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Netherlands, considers approaches for improving the cure rate of MM; from introducing earlier more active agents, to achieving measur...
by:VJHemOnc | 7 views
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses clinical trials that are currently investigating the effects of single-dose drugs and combination therapy for the management of relapsed/refrac​tory multiple myeloma (MM). The OPTIMISMM trial (NCT01...
by:VJHemOnc | 5 views
After promising results form the CHAMPION 1 study (NCT01677858), which increased median progression-fre​e survival to >1 year for relapsed/refrac​tory multiple myeloma (MM) patients with a once-weekly therapy of carfilzomib and dexamethasone (Kd), the ARROW trial (NCT02412878) was set up to investigate whether Kd treatment was more effective with ...
by:VJHemOnc | 6 views
Acute lymphoblastic leukemia (ALL) treatment regimens are long and debilitating, which is especially hard on young adults who are already going through a transitional phase of their lives; this makes providing a support system even more crucial. Here, Wendy Stock, MD, from the University of Chicago Medical Centre, Chicago, IL, emphasizes the need t...
by:VJHemOnc | 4 views
With the remarkable success of the US Bone Marrow Transplant Clinical Trials Network (BMT CNT), founded by Mary Horowitz, in running successful prospective transplantation clinical trials, it is only expected that the UK would want to emulate this success. Heres, Charles Craddock, CBE, FRCP (UK), FR...
by:VJHemOnc | 4 views
Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important to establish standardized protocols to effectively detect and monitor MRD. At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, he...
by:VJHemOnc | 3 views
In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, discusses the importantance of involving the patient in the treatment decision-making process. Dr Levis emphasizes the need to not only educate physicians on the newest treatment options, but also th...
by:VJHemOnc | 1 views
The prognosis for relapsed/refrac​tory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies are showing promising results. Here, Wendy Stock, MD, of the University of Chicago Medical Centre, Chicago, IL, discusses the use of inotuzumab o...
by:VJHemOnc | 5 views